Table 4.

Recommendations on treatment of cancer outpatients with mild COVID-19 (WHO score 1–3).

Population	Intention	Intervention	SoR	QoE	Reference
Cancer patients with COVID-19 – outpatient, mild [1–3]	To prevent hospitalisation and/or death	Anti-S monoclonal antibodiesa	A	IIt	[[21], [22], [23],72]
Cancer patients with COVID-19 – outpatient, mild [1–3]	To prevent hospitalisation and/or death	High-titer convalescent plasma	C	IIt	[[73], [74], [75]]
Cancer patients with COVID-19 – outpatient, mild [1–3]	To prevent hospitalisation and/or death	Nirmatrelvir/ritonavir	A	IIt	[25]
Cancer patients with COVID-19 – outpatient, mild [1–3]	To prevent hospitalisation and/or death	Remdesivir	B	IIt	[26]
Cancer patients with COVID-19 – outpatient, mild [1–3]	To prevent hospitalisation and/or death	Molnupiravir	C	IIt	[24]

COVID-19, coronavirus 2019; QoE, quality of evidence; SoR, strength of recommendation; WHO, World Health Organisation.

^aIf available against the locally predominant SARS-CoV-2 variant, particularly indicated in unvaccinated patients or those at risk of poor vaccine response.